HEPATITIS B, CHRONIC

This study tested a new two-step treatment for adults with chronic hepatitis B who are already on standard antiviral pills. First, participants received an experimental drug (ASO) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could…

This study tested new combinations of drugs in 281 adults with chronic hepatitis B who had stable liver function and were already on standard antiviral therapy. The goal was to see if these combinations could clear the hepatitis B surface antigen (a key marker of infection) and k…

This early-stage study tested new drug combinations in 33 adults with chronic hepatitis B. The goal was to see if the treatments could lower the virus to undetectable levels and reduce a key marker of infection (HBsAg). While not a cure, the approach aims to better control the di…

This study tested a new medicine called bepirovirsen in 981 adults with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if bepirovirsen could suppress the virus enough to allow patients to stop all hepatitis B treatments and stay virus-free…

This study tests a new drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the drug is safe and can lower the amount of virus in the body. About 129 participants will receive injections o…

This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely reduce or eliminate hepatitis B virus in people with chronic infection. 244 adults with stable hepatitis B took part. The main goals …